Wayne J Morgan, Cm

List of Publications by Year in Descending Order

93 papers	6,790 citations	35 h-index	82 g-index
97 ext. papers	7,772 ext. citations	4.9 avg, IF	5.19 L-index

#	Paper	IF	Citations
93	Bronchoalveolar lavage profiles in uncontrolled wheezy children compared by asthma predictive index. *Pediatric Pulmonology*, **2022**, 57, 293-299	3.5	0
92	Association of Intensity of Antipseudomonal Antibiotic Therapy With Risk of Treatment-Emergent Organisms in Children With Cystic Fibrosis and Newly Acquired Pseudomonas Aeruginosa. *Clinical Infectious Diseases*, **2021**, 73, 987-993	11.6	2
91	Further evidence that sex matters in lung development: maternal asthma and infant lung function. *Thorax*, **2021**, 76, 959-960	7.3	
90	Epidemiologic Study of Cystic Fibrosis: 25 years of observational research. *Pediatric Pulmonology*, **2021**, 56, 823-836	3.5	3
89	Diagnostic Accuracy of Nasopharyngeal Swab Cultures in Children Less Than Five Years with Chronic Wet Cough.. *Children*, **2021**, 8,	2.8	1
88	OSA and Neurocognitive Impairment in Children With Congenital Heart Disease. *Chest*, **2020**, 158, 1208-1217	5.3	6
87	Heterogeneity of Mild to Moderate Persistent Asthma in Children: Confirmation by Latent Class Analysis and Association with 1-Year Outcomes. *Journal of Allergy and Clinical Immunology: in Practice*, **2020**, 8, 2617-2627.e4	5.4	9
86	Tobacco smoke exposure and socioeconomic factors are independent predictors of pulmonary decline in pediatric cystic fibrosis. *Journal of Cystic Fibrosis*, **2020**, 19, 783-790	4.1	13
85	Dr Jeffrey S. Wagener: An impactful career and life. *Pediatric Pulmonology*, **2020**, 55, 826-827	3.5	
84	Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis. *Pediatric Pulmonology*, **2020**, 55, 828-834	3.5	8
83	Oral antibiotic prescribing patterns for treatment of pulmonary exacerbations in two large pediatric CF centers. *Pediatric Pulmonology*, **2020**, 55, 3400-3406	3.5	2
82	Predictors of pulmonary exacerbation treatment in cystic fibrosis. *Journal of Cystic Fibrosis*, **2020**, 19, 407-414	4.1	7
81	Mother Knows Best? Comparing Child Report and Parent Report of Sleep Parameters With Polysomnography. *Journal of Clinical Sleep Medicine*, **2019**, 15, 111-117	3.1	22
80	Phenotypes of Recurrent Wheezing in Preschool Children: Identification by Latent Class Analysis and Utility in Prediction of Future Exacerbation. *Journal of Allergy and Clinical Immunology: in Practice*, **2019**, 7, 915-924.e7	5.4	24
79	Pulmonary exacerbations and acute declines in lung function in patients with cystic fibrosis. *Journal of Cystic Fibrosis*, **2018**, 17, 496-502	4.1	9
78	Spirometry and Impulse Oscillometry in Preschool Children: Acceptability and Relationship to Maternal Smoking in Pregnancy. *Journal of Allergy and Clinical Immunology: in Practice*, **2018**, 6, 1596-1603.e6	5.4	14
77	Association of High-Dose Ibuprofen Use, Lung Function Decline, and Long-Term Survival in Children with Cystic Fibrosis. *Annals of the American Thoracic Society*, **2018**, 15, 485-493	4.7	38

76	Health insurance and use of recommended routine care in adults with cystic fibrosis. *Clinical Respiratory Journal*, **2018**, 12, 1981-1988	1.7	7
75	Prenatal fine particulate exposure associated with reduced childhood lung function and nasal epithelia GSTP1 hypermethylation: Sex-specific effects. *Respiratory Research*, **2018**, 19, 76	7.3	20
74	sensitisation at age 6 years is associated with subsequent airway hyper-responsiveness in non-asthmatics. *Thorax*, **2018**, 73, 1170-1173	7.3	4
73	Cystic fibrosis clinical characteristics associated with dornase alfa treatment regimen change. *Pediatric Pulmonology*, **2018**, 53, 43-49	3.5	5
72	Prenatal nitrate air pollution exposure and reduced child lung function: Timing and fetal sex effects. *Environmental Research*, **2018**, 167, 591-597	7.9	14
71	Treatment Setting and Outcomes of Cystic Fibrosis Pulmonary Exacerbations. *Annals of the American Thoracic Society*, **2018**, 15, 225-233	4.7	21
70	Lung function decline is delayed but not decreased in patients with cystic fibrosis and the R117H gene mutation. *Journal of Cystic Fibrosis*, **2018**, 17, 503-510	4.1	10
69	Sleep-Disordered Breathing is Associated With Increased Mortality in Hospitalized Infants With Congenital Heart Disease. *Journal of Clinical Sleep Medicine*, **2018**, 14, 1551-1558	3.1	10
68	Exercise Stroke Volume in Adult Cystic Fibrosis: A Comparison of Acetylene Pulmonary Uptake and Oxygen Pulse. *Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine*, **2018**, 12, 1179548418790564	3.4	2
67	Socioeconomic Status, Smoke Exposure, and Health Outcomes in Young Children With Cystic Fibrosis. *Pediatrics*, **2017**, 139,	7.4	37
66	BMI fails to identify poor nutritional status in stunted children with CF. *Journal of Cystic Fibrosis*, **2017**, 16, 158-160	4.1	11
65	Risk factors for mortality before age 18 years in cystic fibrosis. *Pediatric Pulmonology*, **2017**, 52, 909-915	3.5	44
64	Relationship of Antibiotic Treatment to Recovery after Acute FEV Decline in Children with Cystic Fibrosis. *Annals of the American Thoracic Society*, **2017**, 14, 937-942	4.7	25
63	Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. *Lancet Respiratory Medicine,the*, **2017**, 5, 107-118	35.1	158
62	Data that empower: The success and promise of CF patient registries. *Pediatric Pulmonology*, **2017**, 52, S44-S51	3.5	15
61	Comparison of FEV reference equations for evaluating a cystic fibrosis therapeutic intervention. *Pediatric Pulmonology*, **2017**, 52, 1013-1019	3.5	6
60	The effect of the affordable care act dependent coverage provision on patients with cystic fibrosis. *Pediatric Pulmonology*, **2017**, 52, 458-466	3.5	13
59	Association of prenatal and early childhood stress with reduced lung function in 7-year-olds. *Annals of Allergy, Asthma and Immunology*, **2017**, 119, 153-159	3.2	22

58	Longitudinal differences in sleep duration in Hispanic and Caucasian children. *Sleep Medicine*, **2016**, 18, 61-6	4.6	33
57	A Distinct Low Lung Function Trajectory from Childhood to the Fourth Decade of Life. *American Journal of Respiratory and Critical Care Medicine*, **2016**, 194, 607-12	10.2	102
56	The relationship between cardiac hemodynamics and exercise tolerance in cystic fibrosis. *Heart and Lung: Journal of Acute and Critical Care*, **2016**, 45, 283-90	2.6	7
55	Forced Expiratory Volume in 1 Second Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function. *Journal of Pediatrics*, **2016**, 169, 116-21.e2	3.6	33
54	The Coupling of Peripheral Blood Pressure and Ventilatory Responses during Exercise in Young Adults with Cystic Fibrosis. *PLoS ONE*, **2016**, 11, e0168490	3.7	4
53	Insomnia, Health-Related Quality of Life and Health Outcomes in Children: A Seven Year Longitudinal Cohort. *Scientific Reports*, **2016**, 6, 27921	4.9	30
52	Reply. *Journal of Pediatrics*, **2016**, 172, 228-9	3.6	
51	Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site. *Pediatric Pulmonology*, **2015**, 50, 431-40	3.5	33
50	Pulmonary function outcomes for assessing cystic fibrosis care. *Journal of Cystic Fibrosis*, **2015**, 14, 376-82	4.1	11
49	Seasonal risk factors for asthma exacerbations among inner-city children. *Journal of Allergy and Clinical Immunology*, **2015**, 135, 1465-73.e5	11.5	111
48	Early Childhood Risk Factors for Decreased FEV1 at Age Six to Seven Years in Young Children with Cystic Fibrosis. *Annals of the American Thoracic Society*, **2015**, 12, 1170-6	4.7	21
47	Clinical outcomes after initial pseudomonas acquisition in cystic fibrosis. *Pediatric Pulmonology*, **2015**, 50, 42-8	3.5	49
46	Early Life Growth Trajectories in Cystic Fibrosis are Associated with Pulmonary Function at Age 6 Years. *Journal of Pediatrics*, **2015**, 167, 1081-8.e1	3.6	39
45	Impaired cardiac and peripheral hemodynamic responses to inhaled □agonist in cystic fibrosis. *Respiratory Research*, **2015**, 16, 103	7.3	11
44	Decline in lung function does not predict future decline in lung function in cystic fibrosis patients. *Pediatric Pulmonology*, **2015**, 50, 856-62	3.5	13
43	Risk factors for lung function decline in a large cohort of young cystic fibrosis patients. *Pediatric Pulmonology*, **2015**, 50, 763-70	3.5	71
42	Modified STOP-Bang Tool for Stratifying Obstructive Sleep Apnea Risk in Adolescent Children. *PLoS ONE*, **2015**, 10, e0142242	3.7	27
41	Clinical use of tobramycin inhalation solution (TOBI□) shows sustained improvement in FEV1 in cystic fibrosis. *Pediatric Pulmonology*, **2014**, 49, 529-36	3.5	16

40	Pseudomonas aeruginosa in vitro phenotypes distinguish cystic fibrosis infection stages and outcomes. *American Journal of Respiratory and Critical Care Medicine*, **2014**, 190, 289-97	10.2	77
39	Early childhood wheezing is associated with lower lung function in cystic fibrosis. *Pediatric Pulmonology*, **2014**, 49, 745-50	3.5	18
38	Liver involvement in the Hispanic population of North America with cystic fibrosis. *Journal of Pediatric Gastroenterology and Nutrition*, **2014**, 59, 476-9	2.8	7
37	Changing thresholds and incidence of antibiotic treatment of cystic fibrosis pulmonary exacerbations, 1995-2005. *Journal of Cystic Fibrosis*, **2013**, 12, 332-7	4.1	16
36	Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents. *Journal of Allergy and Clinical Immunology: in Practice*, **2013**, 1, 163-71	5.4	49
35	Probability of treatment following acute decline in lung function in children with cystic fibrosis is related to baseline pulmonary function. *Journal of Pediatrics*, **2013**, 163, 1152-7.e2	3.6	25
34	Does COPD begin in childhood?. *Lancet Respiratory Medicine,the*, **2013**, 1, 282-4	35.1	1
33	Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis. *Pediatric Pulmonology*, **2013**, 48, 666-73	3.5	82
32	Pulmonary exacerbations in cystic fibrosis: young children with characteristic signs and symptoms. *Pediatric Pulmonology*, **2013**, 48, 649-57	3.5	33
31	Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis. *Pediatric Pulmonology*, **2013**, 48, 943-53	3.5	25
30	Multiple antibiotic-resistant Pseudomonas aeruginosa and lung function decline in patients with cystic fibrosis. *Journal of Cystic Fibrosis*, **2012**, 11, 293-9	4.1	42
29	Risk factors for rate of decline in FEV1 in adults with cystic fibrosis. *Journal of Cystic Fibrosis*, **2012**, 11, 405-11	4.1	83
28	Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort. *Journal of Cystic Fibrosis*, **2012**, 11, 446-53	4.1	61
27	Lung function decline from adolescence to young adulthood in cystic fibrosis. *Pediatric Pulmonology*, **2012**, 47, 135-43	3.5	77
26	Socioeconomic status and the likelihood of antibiotic treatment for signs and symptoms of pulmonary exacerbation in children with cystic fibrosis. *Journal of Pediatrics*, **2011**, 159, 819-824.e1	3.6	27
25	Clinical use of dornase alpha is associated with a slower rate of FEV1 decline in cystic fibrosis. *Pediatric Pulmonology*, **2011**, 46, 545-53	3.5	66
24	Location and duration of treatment of cystic fibrosis respiratory exacerbations. *American Journal of Respiratory and Critical Care Medicine*, **2011**, 184, 278; author reply 279	10.2	5
23	Year-to-year changes in lung function in individuals with cystic fibrosis. *Journal of Cystic Fibrosis*, **2010**, 9, 250-6	4.1	81

22	Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohort. *Pediatric Pulmonology*, **2010**, 45, 934-44	3.5	43
21	Pulmonary outcome prediction (POP) tools for cystic fibrosis patients. *Pediatric Pulmonology*, **2010**, 45, 1156-66	3.5	34
20	Trends in the use of routine therapies in cystic fibrosis: 1995-2005. *Pediatric Pulmonology*, **2010**, 45, 1167-72	3.5	47
19	Relationship between inhaled corticosteroid therapy and rate of lung function decline in children with cystic fibrosis. *Journal of Pediatrics*, **2008**, 153, 746-51	3.6	65
18	Trends in the clinical characteristics of the U.S. cystic fibrosis patient population from 1995 to 2005. *Pediatric Pulmonology*, **2008**, 43, 739-44	3.5	17
17	Presence of methicillin resistant Staphylococcus aureus in respiratory cultures from cystic fibrosis patients is associated with lower lung function. *Pediatric Pulmonology*, **2007**, 42, 513-8	3.5	111
16	Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. *Journal of Pediatrics*, **2007**, 151, 134-9, 139.e1	3.6	328
15	Infant care patterns at epidemiologic study of cystic fibrosis sites that achieve superior childhood lung function. *Pediatrics*, **2007**, 119, e531-7	7.4	48
14	Impact of pregnancy on women with cystic fibrosis. *Chest*, **2006**, 129, 706-11	5.3	134
13	Factors predicting the persistence of asthma insights from the Tucson children respiratory study. *Revue Francaise D allergologie Et D immunologie Clinique*, **2005**, 45, 542-546		2
12	Clinical Screening of School Children for Polysomnography to Detect Sleep-Disordered Breathing The Tucson Children Assessment of Sleep Apnea Study (TuCASA). *Journal of Clinical Sleep Medicine*, **2005**, 01, 247-254	3.1	51
11	Factors influencing outcomes in cystic fibrosis: a center-based analysis. *Chest*, **2003**, 123, 20-7	5.3	169
10	Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis. *Journal of Pediatrics*, **2003**, 142, 624-30	3.6	292
9	Feasibility of using unattended polysomnography in children for research--report of the Tucson Children's Assessment of Sleep Apnea study (TuCASA). *Sleep*, **2001**, 24, 937-44	1.1	122
8	Epidemiologic study of cystic fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada. *Pediatric Pulmonology*, **1999**, 28, 231-41	3.5	147
7	Patterns of medical practice in cystic fibrosis: part I. Evaluation and monitoring of health status of patients. Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. *Pediatric Pulmonology*, **1999**, 28, 242-7	3.5	35
6	Patterns of medical practice in cystic fibrosis: part II. Use of therapies. Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. *Pediatric Pulmonology*, **1999**, 28, 248-54	3.5	72
5	Estimating effectiveness in an observational study: a case study of dornase alfa in cystic fibrosis. The Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. *Journal of Pediatrics*, **1999**, 134, 734-9	3.6	24

4	Epidemiologic study of cystic fibrosis: Design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada **1999**, 28, 231		3
3	Asthma and wheezing in the first six years of life. The Group Health Medical Associates. *New England Journal of Medicine*, **1995**, 332, 133-8	59.2	2919
2	Infants with upper respiratory illnesses have significant reductions in maximal expiratory flow. *Pediatric Pulmonology*, **1990**, 9, 91-5	3.5	18
1	Airway responsiveness to cold, dry air in normal infants. *Pediatric Pulmonology*, **1988**, 4, 90-7	3.5	59